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INTRODUCTION
Cytopenias are very commonly seen in HIV-infected
individuals, particularly in the late stages of disease. Several
mechanisms have been postulated, all of which may con-
tribute to the hematopoietic defects seen in these patients.
The first and most straightforward explanation is that the
antiretroviral drug regimens used to treat infection induce
myelosuppression [1]. This is unlikely to account in entirety,
however, for the wide range of cytopenias observed. A sec-
ond explanation for hematopoietic dysfunction is that a sub-
set of progenitor cells is directly infected with HIV. For this
to be feasible, the subset of cells must express the CD4
receptor required for HIV infection at some point during
their maturation process. In support of this, several groups
including our own have demonstrated the existence of
CD34+CD4+ cells [2–8]. These reports have indicated a
wide range of expression of CD4 on CD34+ cells, from 1 to
65%. We and others have shown that the CD4 molecule
present on CD34+ cells is capable of binding gp120 [8,9],
suggesting that even in the absence of direct HIV infection,
the CD34+CD4+ cell could interact with HIV, resulting in
impairment [10]. Such an impairment could have devastat-
ing effects on hematopoiesis, since depletion or alteration of
the earliest progenitor cells could affect all differentiated
progeny cells such as granulocytes, myeloid cells, erythro-
cytes, and T and B cells. Thus, a third potential explanation
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ABSTRACT
Pancytopenia as a consequence of bone marrow abnormalities is commonly seen in HIV-infected individuals. To
examine the effect that HIV-1 has on hematopoietic cells, we compared hematopoietic properties of bone marrow
samples from HIV+ patients at various stages of disease with bone marrow samples from uninfected donors. While
the absolute number of recovered CD34+ cells and the cloning efficiency of these cells did not differ significantly in
HIV+ donors, the percentage of CD34+CD4+ cells was significantly depleted in late-stage HIV+ patients. We
observed a direct correlation between the numbers of CD34+CD4+ cells in the bone marrow and the peripheral
CD4 count. Further characterization of the CD34+CD4+ subpopulation demonstrated that these cells expressed
lower levels of HLA-DR on their surface compared with CD34+CD4– cells, suggesting an immature phenotype. We
also found evidence for expression of HIV-1 coreceptors CXCR-4 and CKR-5 message and protein in CD34+ bone
marrow cells. While this finding suggested that hematopoietic cells might be susceptible to HIV infection at an
early stage of maturation, thus affecting different cell lineages as they matured, we did not find any evidence for
infection of HIV in these cells. These data suggest that HIV affects early hematopoietic progenitor cells either
directly or indirectly, and in particular CD34+CD4+ cells. This finding has important implications for disease patho-
genesis and for application of gene therapy approaches that use CD34+ hematopoietic cells. 
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for hematopoietic dysfunction could be indirect effects of
HIV on early cells in the absence of productive infection. 
The presence of proviral DNA in purified bone marrow
CD34+ cells from HIV-infected patients seems very rare or
absent [11–13]. Some studies have shown active viral repli-
cation at the bone marrow level [14–18]; these infected cells
may be either monocyte precursors [14,17] or megakaryo-
cytes [15]. It has been reported that bone marrow stromal
cells are infected with HIV-1 in vivo; as a consequence, the
production of certain stromal cell–derived hematopoietic
growth factors is deficient [19]. While these studies suggest
direct infection of HIV in a subset of hematopoietic cells,
efforts to detect viral sequences in CD34+ cells have been
largely unsuccessful [12,20–24]. 
Susceptibility to HIV infection would require not only
expression of CD4 on the cell surface but also coexpression
of one of the HIV coreceptors. Two such coreceptors have
recently been identified, CXCR-4 [25–29] and CKR-5
[30–32]. They have been referred to in the literature as R4
and R5, respectively. CXCR-4 provides a point of entry for
HIV grown in T cell lines but not for primary isolates [25].
CKR-5 is important for the entry of macrophage tropic
HIV isolates, and its mRNA has been detected in cell types
susceptible to infection with these isolates [32]. Our data
here support the findings by Deichmann et al. [7] that
CD34+ cells express message for CXCR-4. Additionally, we
show that message for CKR-5 and protein for both corecep-
tors is present in these cells. The cells do not contain HIV
RNA or DNA at detectable levels, however.
In this study, we analyzed the hematopoietic properties
of eight bone marrow CD34+ cell samples derived from
HIV-infected donors with various CD4 counts, and also of
11 bone marrow samples from HIV-negative control
donors. Our data support the existence of CD34+CD4+
hematopoietic cells, demonstrate that these cells are signifi-
cantly depleted in bone marrow of late-stage HIV-infected
individuals, and show that these cells are enriched for HLA-
DRlow–expressing cells, suggesting a primitive phenotype.
Although these cells appear to express coreceptor message
and protein, and thus should be susceptible to HIV infec-
tion [7 and this study], we did not find any evidence for
HIV-1 RNA or DNA in these cells. These results raise the
possibility that the CD34+CD4+ cells could be depleted by
indirect mechanisms such as gp120-induced, fas-mediated
apoptosis [8,10,33,34]. This would have important implica-
tions for disease pathogenesis and for use of these cells for
gene therapy and hematopoietic reconstitution. A better
understanding of the effects that HIV-1 exerts on CD34+
cell maturation may lead to therapeutic interventions to
improve hematopoiesis in HIV-infected individuals.
PATIENTS AND METHODS
Sources of normal and HIV-1–infected bone marrow
Bone marrow (BM) from adult HIV-1–seronegative
donors was obtained as residual material from the Universi-
ty of Colorado Bone Marrow Transplantation Unit
(BMTU). Eight BM samples from HIV-1–seropositive
donors were obtained using Institute Review Board (IRB)-
approved protocols of University of Colorado Health Sci-
ences Center from seven patients who gave informed con-
sent. One patient donated bone marrow twice at a 6-month
interval (samples 1 and 5). The median age of HIV-1–infect-
ed patients was 38 years (27–49). The median CD4 count
was 153 cells/mm3 (27–640). Four HIV+ patients had
advanced AIDS with opportunistic infections or malignan-
cies. One patient had AIDS without opportunistic infections
or malignancies; the remaining two patients did not have
AIDS and had relatively high CD4 counts. Patient informa-
tion for the HIV+ BM donors is shown in Table 1. All
patients had received treatment with protease inhibitors in a
triple-therapy regimen except patient 2, who for medical
reasons received only AZT. Approximately 60 mL of bone
marrow was aspirated from the posterior iliac crest of each
donor and collected in heparinized 60-mL tubes. 
CD34+ selection of bone marrow cells
BM samples were diluted with column buffer (13 phos-
phate-buffered saline, 0.2% human serum albumin, 5 mM
EDTA) and then subjected to Ficoll-Hypaque gradient cen-
trifugation. Mononuclear cells were collected and washed
twice with column buffer, and 2.43108 cells were incubated
with 240 µL A1 blocking reagent (human IgG) and 240 µL
A2 blocking reagent (QBEND/10, mouse IgG1) together
for 15 minutes at 4°C. Cells were washed once with column
buffer, followed by incubation with 240 µL colloidal super-
Table 1. Clinical status of HIV + BM donors
AIDS? Current 
Sample Peripheral blood Viral burden (opportunistic infections/ antiretroviral 
no. CD4 cells/mm3 (viral copies/mL) associated malignancies) medication
1 27 50,112 Yes (none/NHL) AZT, ddI, saquinavir
2 30 125,000 Yes (none/none) AZT
3 96 <400 Yes (thrush, MAI/none) d4T, 3TC, indianavir
4 41 71,608 Yes (none/none) 3TC, ddI, saquinavir
5* 348 400 Yes (none/NHL in remission) d4T, 3TC, indianavir
6 520 1600 No d4T, 3TC, nelfinavir
7 640 600 No d4T, 3TC, indianavir
8 209 6000 No d4T, nelfinavir, nevirapine
Viral burden was determined by RT-PCR. 3TC, lamivudine; AZT, zidovudine; d4Y, stavudine; ddI, didanosine; MAI, macobacterium avium intercellular;
NHL, non-Hodgkin’s lymphoma.
*Sample 5 was taken from the same patient 6 months after sample 1.
paramagnetic MACS microbeads (B1) for 15 minutes at
4°C, then washed again with 13 column buffer. CD34+ cells
were purified using VS+ separation columns (large columns)
on VarioMACS (Miltenyi Biotec, Auburn, CA). To obtain
higher purity, cells were fractionated two times on separate
VS+ columns. Purity of CD34+ was examined via fluores-
cence-activated cell sorting (FACS) by staining 13105 cells
with phycoerythrin (PE) (Becton Dickinson, San Jose, CA),
fluorescein isothiocyanate (FITC) (Becton Dickinson), or
Tricolor (TC) (Caltag Laboratories, San Francisco, CA)
conjugated antibodies. Purity of CD34+ cells by FACS
analysis averaged 88.8% (median 94.7%) and 91.6% (medi-
an 93.0%) for BM from HIV+ and HIV– donors, respective-
ly. Final yields from BM aspirates were 2.0–5.73106 and
0.12–6.23106 CD34+ cells from HIV – and HIV + donors,
respectively. Because of limited cell numbers, not all analy-
ses were performed on all samples. 
FACS analysis on bone marrow CD34+ cells 
CD34+ bone marrow cells from HIV – and HIV+ indi-
viduals were analyzed for the presence of CD4. Purified
CD34+ bone marrow cells (13105) were stained with a mix-
ture of PE- and FITC-conjugated anti-CD34 and anti-CD4
monoclonal antibodies (Leu 3a; Becton Dickinson). As an
isotype control, a mixture of matched IgG1 isotype PE- and
FITC-conjugated antibodies were used in all FACS analy-
ses. Staining procedure was according to our published
studies [8]. Cursors were set based on the matched isotype
controls. To further characterize the phenotype of the
CD34+CD4+ and CD34+CD4– cells, expression of HLA-DR
on the cell surface was measured using tricolor immunofluo-
rescence FACS with the following antibodies: FITC-conju-
gated HLA-DR (Becton Dickinson), PE-conjugated anti-
CD4, and TC anti-CD34 (Caltag Laboratories). 
CD34+ bone marrow cells from HIV– donors were also
examined for the presence of HIV second coreceptor pro-
teins CXCR-4 and CKR-5. Cells (23105) were incubated
for 20 minutes in the dark at 4°C with anti-CXCR-4 (PE-
conjugated) and anti-CKR-5 (FITC-conjugated) monoclo-
nal antibodies (Pharmigen, San Diego, CA). Matched iso-
type controls IgG2ak (PE) and IgG2ak (FITC) were also
used to set the cursors. In parallel, HOS-CD4 [31] and sta-
bly transfected 293 cells expressing CKR-5 were used as
positive controls. 
Methylcellulose assay on mononuclear and CD34+-purified
bone marrow cells
Methylcellulose colony (MC) formation assay was used
to determine the colony-forming capability of CD34+ cells
derived from total mononuclear cells (MNCs) and CD34+-
purified BM cells from HIV+ and HIV– donors. For MNCs,
33105 cells were used; for CD34+-purified cells, 23103 cells
were used. Cells were plated in 35-mm2 petri dishes after
resuspending in 200 µL Iscove’s modified Dulbecco’s medi-
um (IMDM) containing 1 mL methylcellulose (44%; Stem
Cell Technologies, Minneapolis, MN), 30% fetal calf serum
(FCS) (not heat-inactivated; Gibco BRL, Grand Island,
NY), bovine serum albumin (1%; Boehringer Mannheim,
Indianapolis, IN), 2-mercaptoethanol (10–4 M), methylpred-
nisolone (10–6 M), erythropoietin (1 U/mL; R&D Systems,
Vancouver, British Columbia, Canada), and interleukin (IL)-
3 (100 U/mL; R&D Systems). Duplicate plates were ana-
lyzed for each sample. Plates were incubated at 37°C with
5% CO2 and humidity. Colonies were counted 11–14 days
after plating and scored for granulocytic/monocytic (GM),
monocytic (M), erythrocytic (BFU-E), and multilineage
(GEMM) colonies. Cloning efficiency (CE) was calculated
as follows:
CE=
Total number of colonies counted
3 100
Total number of cells plated 
Polymerase chain reaction (PCR) on bone marrow cells 
for fusin coreceptor (CXCR-4), CKR-5, and HIV reverse
transcriptase (HIV-RT)
Nested PCR for HIV-RT has been previously described
[35]. For RT-PCR, 23106 MNCs and 1–23106 CD34+-
purified bone marrow cells from HIV+ patients were used to
extract total cellular RNA using Trizol reagent (Gibco) as
described in detail by the manufacturer. The RNA pellet
was resuspended in 33 µL RNAse-free MilliQ water and
stored at –70°C until used for cDNA synthesis. Before
cDNA synthesis, all samples were treated with 1 µL DNase
1 (Gibco) to remove the contaminating DNA and 1 µL
RNasin (Promega, Madison, WI) to protect from RNA
degradation. cDNA synthesis was performed as previously
described [36]. Primers for CXCR-4 were selected using the
MacVector program. CXCR-4 primers were: CAAGG
CAGTCCATGTCATCTACAC (sense) and TGCACAGT
GTTCTCAAACTCACACC (antisense), amplifying a
sequence of 516 bp. Nested primers used to amplify CKR-5
have been published [7], generating a band of 491 bp. PCR
analysis was performed as previously described [35]. The
PCR conditions used allowed us to detect one copy in 103
cells (not shown). As a control for contaminating DNA, all
samples were run with and without reverse transcriptase
(RT). In a parallel reaction, b-actin message was amplified
to adjust for the amount of RNA in the reaction. Primers to
b-actin have been described [37]. HOS-CD4 cells, used as a
positive control for CXCR-4 and CKR-5, were grown as
described [31]. In some cases, peripheral blood mononuclear
cells, either freshly isolated or grown with 100 U/mL IL-2
(kindly provided by Hoffman-LaRoche, Nutley, NJ) and 4
µg/mL phytohemagglutinin (PHA), were used as controls
for PCR. Amplification products were resolved on a 1%
agarose gel using 13 Tris acetate EDTA (TAE) buffer. A
123-bp DNA ladder was used as a molecular weight marker.
After electrophoresis, the agarose gels were stained with
ethidium bromide, visualized, and photographed.
DNA-based PCR for RT and b-actin used the same
conditions as described above for RT-PCR, except that only
external amplification was used to amplify RT. To increase
sensitivity of detection, we used chemiluminescence with
biotinylated probes using the Phototope-Star Detection Kit
(New England Biolabs, Beverly, MA), as described by the
manufacturer. 
Statistical analysis
Comparison of independent samples was carried out
using nonparametric (usually randomization test) techniques
when sample sizes were small or parametric techniques (Stu-
dent’s t test) when the necessary assumptions were satisfied.
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The relationship between peripheral CD4 count and
CD34+CD4+ percentage in the bone marrow was character-
ized using standard linear regression techniques. Averages
are expressed as mean ± standard deviation (SD).
RESULTS
A total of eight BM samples from seven HIV-infected
patients with various CD4 counts and 11 samples from
uninfected controls were analyzed. HIV+ samples are identi-
fied as numbered samples according to patient number
(Table 1). Table 1 shows the CD4 count, viral burden, and
current antiretroviral drug regimens for the donors. Sam-
ples were analyzed for total number of CD34+ cells as a ratio
of total MNC cells, cloning efficiency in methylcellulose,
percentage of CD34+CD4+ cells, PCR and p24 assays for
HIV, and PCR for CXCR-4 and CKR-5. 
Recovery of CD34+ bone marrow cells from HIV+ patients
There was no apparent difference in the purity of
CD34+ preparations from HIV + vs. HIV – donors (average
88.8 and 91.6%, respectively). The total number of purified
CD34+ cells as a ratio of total MNC cells is shown in Fig. 1.
The average ratio for HIV+ donors was 0.49 ± 0.44%, com-
pared with 0.91 ± 0.86% for HIV–. This trend toward lower
CD34+ cell recovery in the HIV+ samples was not significant
(p > 0.05), and appeared to depend on two HIV – samples
(samples 2 and 3) that had higher-than-average ratios.
There did not appear to be a consistent relationship
between the CD34+/MNC ratio and clinical state of the
patient (as measured by CD4 count, viral burden, and
accompanying diseases; see Table 1).
Cloning efficiency of purified CD34+ bone marrow cells
from HIV+ patients
The clonogenic potential of purified CD34+ cells derived
from HIV+ and HIV– donors is shown in Fig. 2. The average
cloning efficiencies were 2.2 ± 3.6 and 1.1 ± 1.2 for HIV+ and
HIV– samples, respectively. This difference was not statisti-
cally significant (p > 0.05). We noticed a significant and con-
sistent difference in the size of the colonies from the HIV+ vs.
HIV– CD34+ cells. In samples from late-stage AIDS patients
(samples 1–4), the colonies were at least fivefold smaller than
colonies from the control BM and had a tendency to die after
12–14 days in methylcellulose culture. Thus, while the differ-
ence between the number of colonies was barely significant,
there was a substantial reduction in colony size and viability
in the HIV+ samples. We did not observe a difference in the
types of colonies obtained, which were primarily G/M or M
for both HIV+ and HIV– samples (not shown).
Decrease of CD34+CD4+ cells in HIV+ patients with AIDS
and correlation with CD4 count
We and others have previously described the existence
of a subset of CD34+CD4+ cells. In the analysis of BM sam-
ples from HIV + patients, we observed a very significant
decrease in this population compared with HIV– controls.
The data in Fig. 3 show an average percentage for this pop-
ulation (expressed per total CD34+ cells) of 10.7 ± 9.2 and
34.8 ± 9.6 in HIV + and HIV – samples, respectively. This
difference was very significant by either parametric or non-
parametric testing (p < 0.005). 
Figure 1. Ratio of bone marrow CD34+cells to total MNC in HIV+
and HIV– samples
Sample numbers for HIV + patients correspond to Table 1. Each value shown
is averaged from two counts for each sample.
Figure 2. Cloning efficiency of hematopoietic bone marrow pro-
genitors in HIV+ and HIV– samples
Each value shown is averaged from duplicate methylcellulose plates.
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From the data in Fig. 3, there appeared to be a positive
correlation between percent CD34+CD4+ cells and CD4
count of the patient (Table 1). We therefore examined this
correlation, shown in Fig. 4. A statistical analysis showed the
correlation to be highly significant, as the slope of the
regression of double-positive percentage vs. CD4 count was
significantly greater than zero (p < 0.002). A test of the
intercept showed that the line went through the origin with
slope 0.035. The r 2 value was 0.87. Thus, the reduction in
CD34+CD4+ cells in HIV + BM was correlated with CD4
count in the patient.
Reduced expression of HLA-DR on CD34+CD4+ cells
compared with CD34+CD4– cells
Reduction in the percentage of CD34+CD4+ cells in
HIV+ patients could have important implications for disease
pathogenesis and might result from either direct (HIV
infection) or indirect (secondary to HIV infection) mecha-
nisms. Impairment of an early cell would be expected to
affect all subsequent lineages of that cell. We therefore
examined expression of HLA-DR (expressed at lower levels
on earlier cells and higher levels on more committed cells)
in CD34+CD4+ cells vs. CD34+CD4– cells using triple-stain-
ing FACS analysis on HIV+ BM sample 7. Figure 5A shows
expression of HLA-DR and CD4 on the starting CD34+
population used for gating in this experiment (gated popula-
tion shown in Fig. 5D). The CD34+CD4+ subpopulation
shown in Fig. 5B was further analyzed for the expression of
HLA-DR (Fig. 5E and F). The results show that the
CD34+CD4+ population expressed relatively low levels
HLA-DR compared with the CD34+CD4– population. The
log intensity of HLA-DR positivity peaked at about 21 for
CD34+CD4+ (Fig. 5F) and 31 for CD34+CD4– (Fig. 5E)
cells. There was thus a 1.5-fold difference in these cell pop-
ulations, consistent with the idea that CD34+CD4+ cells are
earlier in their hematopoietic maturation than CD34+CD4–
cells. Similar results were obtained with the CD38 marker
and with CD34+ cells isolated from cord blood of HIV –
donors (data not shown). 
Consistent with the hypothesis that CD34+CD4+ cells
are earlier than CD34+CD4– cells, we also observed in these
cells a slightly increased cloning efficiency (4.95 vs. 3.58%,
respectively) and a higher percentage of BFU-E colonies in
methylcellulose (1.5 vs. 0% of total colonies, respectively;
data not shown).
CD34+ cells from HIV+ donors express the CXCR-4 and
CKR-5 coreceptors
Two BM samples were analyzed for expression of
CXCR-4 and CKR-5 HIV coreceptors both before and
after CD34+ cell purification, along with positive controls.
RT-PCR with control b-actin is shown in Fig. 6. All samples
were also run through PCR without RT as a negative con-
trol. The positive controls, fresh peripheral blood mononu-
clear cells and HOS CD4 cells, were positive for b-actin
(bottom), CXCR-4 (top), and CKR-5 (middle). Similarly, all
BM samples tested (MNC before CD34+ selection and the
purified CD34+ cells) were positive for b-actin, CXCR-4,
and CKR-5. In all cases, the samples without RT were nega-
tive. Thus, CXCR-4 and CKR-5 were expressed in the two
HIV+ BM samples examined, both before and after CD34+
selection.
Figure 3. Significant depletion of CD34+CD4+ cells in bone marrow
from HIV-1–infected patients
The percentage of CD34+CD4+ cells per total CD34+ cells is compared in
HIV + and HIV – samples. Each value is from a single FACS analysis.
h CD34+CD4+
Figure 4. Positive correlation between CD34+CD4+ bone marrow
cells and peripheral CD4+ T cells
The correlation is shown between percentage of CD34+CD4+ cells (as shown in
Fig. 3) and peripheral CD4 count of the patients. Linear regression analysis
was used to fit the line (see MATERIALS AND METHODS).
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CD34+ cells from HIV– donors express CXCR-5 and CKR-5
receptors on their surface
CD34+ cells from HIV– bone marrow samples were ana-
lyzed for the surface expression of CXCR-4 and CKR-5
(Fig. 7). Isotype controls are shown in Fig. 7A and D.
Although both were expressed on a subset of CD34+ cells,
the percentage of cells expressing CXCR-4 (76.2%; Fig. 7B)
was much higher than the percentage of cells expressing
CKR-5 (9.7%; Fig. 7E). As positive controls, cell lines
HOS-CD4 and transduced 293 cells were used for CXCR-4
and CKR-5, respectively (Fig. 7C and F).
PCR analysis for HIV sequences
RT-PCR using nested primers for HIV-RT was per-
formed on HIV+ BM samples 5 (MNC only), 6 (MNC and
CD34+-selected), and 7 (MNC and CD34+-selected). We
did not detect any HIV message in any of these preparations
(Fig. 8). All samples did, however, exhibit a positive b-actin
signal (Fig. 6, bottom panel). Thus, hematopoietic MNC
and CD34+ cell populations from these patients (who were
relatively healthy; see Table 1) did not express HIV
sequences. 
We also examined for the presence of proviral sequences
using DNA-based PCR in some of the samples. These data
are shown in Fig. 9. Although all samples tested clearly
showed a b-actin band, RT sequences were not amplified in
any of the samples, even using sensitive chemiluminescent
detection. CD34+ and MNC fractions, as well as dozens of
MC colonies tested, were also all negative for HIV produc-
tion by the p24 assay (data not shown). 
Figure 5. Low expression of HLA-DR on CD34+CD4+ cells compared with CD34+CD4– cells
A. Expression of HLA-DR and CD4+ on the starting CD34+ population. B. Gating on the CD34+CD4+ and CD34+CD4– subpopulations. C. Overall expression of
HLA-DR on CD34+ total cells. D. Purity of gated CD34+ population. Mean fluorescence intensity of HLA-DR on CD34+CD4– (E) and CD34+CD4+ (F) cells. 
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DISCUSSION
Our major finding was a highly significant depletion of
the subpopulation of CD34+CD4+ cells in late-stage HIV+
infection. There was also a statistically nonsignificant trend
toward diminished recovery of CD34+ cells and impaired
clonogenic efficiencies in BM of HIV+ patients. In the seven
BM samples examined for CD34+CD4+, we found the per-
centage of this subpopulation to correlate positively with the
CD4 count of the patient. One patient donated two separate
BM samples 6 months apart (samples 1 and 5). At the time
sample 1 was taken, the patient was acutely ill with non-
Hodgkin’s lymphoma (NHL) and had a CD4 count of 27.
The percentage of CD34+ cells that were also CD4+ was 7%
at that time. Six months later, the patient’s NHL was in
remission, and with triple antiretroviral therapy, the CD4
count increased to 348. This was accompanied by a slight
increase in the percentage of CD34+CD4+ cells, to 10.5%.
This increase is interesting, but whether or not it is signifi-
cant is unclear. If an increase in CD4 count is in fact corre-
lated with an increase in CD34+CD4+ cells, this subpopula-
tion might be renewable even in late-stage HIV+ patients.
Continued analysis of multiple samples from this and other
patients will be necessary to determine whether such a cor-
relation exists and whether an increase in CD34+CD4+ cells
is correlated with positive clinical outcomes. 
Other investigators have also described some level of
impairment of CD34+ cells in HIV+ patients. Various studies
have reported alteration in the number or type of clono-
genic cells derived from HIV+ BM. In one study, the num-
ber of CFU-GM and BFU-E colonies derived from BM of
six HIV-infected patients was found to be unaltered [11]. In
other studies, the numbers of CFU-GM [13,38,39] and
megakaryocyte progenitors [39] were found to be signifi-
cantly reduced. Differences in these studies might be
explained by limited patient samples and the disease stage of
the patients. A study by Kearns et al. [23] indicated that the
percentage of CD34+ cells and the clonogenic potential of
these cells were reduced in patients with low CD4 counts
but not in patients with higher CD4 counts. Marandin et al.
[22] reported that while CD34+CD38+ cells were not
reduced in number or potential as judged by long-term cul-
ture initiating cell (LTC-IC) assays, the more primitive
CD34+CD38– cells were in fact impaired. All of the patients
in this study had CD4 counts <300. In a study by Junker et
al. [24] with asymptomatic HIV-infected donors, hemato-
poietic cells from mobilized blood were not impaired. Thus,
other recent studies are in agreement with our data present-
ed here, suggesting that impairment of hematopoiesis
depends on the disease stage of the patient. Since antiretro-
viral drugs are known to affect hematopoietic cells, as more
patients receive the now-standard triple combination thera-
py, more consistency in the data for the different patient
populations should be forthcoming.
To our knowledge, this is the first report showing a
significant depletion of the CD34+CD4+ subpopulation in
late-stage HIV + patients. We present data here, consistent
with the findings of others [2–4,6,7], that this subpopulation
displays a phenotype likely to represent a more immature cell
than the CD34+CD4– cell, based here on clonogenic assays
and low expression of HLA-DR. Louache et al. [3] showed
that the CD34+CD4+CD38lowHLA-DRlow subpopulation was
enriched for LTC-IC compared with the CD34+CD4– sub-
population. Similarly, Muench et al. [6] and Zauli et al. [2]
showed that these cells have an immature phenotype and
higher proliferative potential than CD34+CD4– cells [6]. We
have also confirmed low expression of CD38 on CD34+ cells
derived from cord blood (not shown). 
HIV effects on these early hematopoietic cells might
translate into impaired differentiation of multiple lineages
that derive from CD34+CD4+ cells. Thus, suppressive
effects of HIV-1 on hematopoietic stem/progenitor cells
have important implications for disease pathogenesis and
therapeutic strategies. In addition to CD4 helper cell deple-
tion, which is a hallmark of HIV infection, a variety of
cytopenias in other blood cell lineages characterized by ane-
mia, neutropenia, and thrombocytopenia, alone or in vari-
ous combinations (pancytopenia), are consistently observed
in HIV-infected patients. The incidence of cytopenias
increases with the stage of the disease [40], and up to 80%
of patients in late-stage disease manifest these conditions
[41]. A plausible explanation for cytopenias of several lin-
eages may lie in an impaired proliferation/differentiation
capacity of the hematopoietic stem cell/progenitor compart-
ment. Impaired replenishment of CD4+ cells as well as other
lineages could occur if CD34+ cells are directly or indirectly
affected by HIV-1.
The role of the CD4 marker on CD34+ cells has not yet
been elucidated. It has been postulated [2] that these cells
might be capable of interacting with class II MHC-positive
Figure 6. CD34+ bone marrow cells expressed HIV-1 second core-
ceptor sequences
RT-PCR for expression of CXCR-4 (top), CKR-5 (middle), and b-actin (bot-
tom). Cells were total mononuclear preparations (MNC) or CD34-selected
(CD34). +/– refers to whether reverse transcriptase was included in the reac-
tion. Control cells were either freshly isolated or PHA + IL-2 blasted peripher-
al blood mononuclear cells, and the HOS-CD4 cell line. MilliQ (MQ) water
was included as a negative control. Sizes are indicated by the 123-bp ladder.
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bone marrow accessory cells; this would be consistent with
the role of CD4 on T cells. Expression of CD4 might enable
these cells to interact with other cell types in the bone mar-
row microenvironment. Alternatively (or in addition), the
CD34+CD4+ cell might be a precursor to mature CD4+ cells
that would migrate into the thymus. While this has not been
demonstrated in in vitro and in vivo systems that mimic thy-
mopoiesis, it is possible that the conditions needed for matu-
ration of the earliest stem cells have not been met in these
systems. If CD34+CD4+ cells in the bone marrow do give rise
to mature CD4+ cells (which is not presently clear), then
alterations in the CD34+CD4+ subpopulation by HIV could
translate into reduced CD4 counts in the periphery. An alter-
native possibility is that patients with low CD4 counts are in
the later stages of disease and often have high viral burdens
(which would depend on treatment regimen as well). The
high viral burden means that more viral particles would be in
the bone marrow environment to affect the CD34+CD4+
cells, either directly or indirectly. 
A critical question that remains unanswered is whether
early hematopoietic cells are susceptible to HIV infection at
any stage. Our data show that BM cells (albeit from relative-
ly healthy HIV + donors) did not contain HIV-1 DNA or
express HIV sequences. Studies from other laboratories
have addressed this question in two different ways. One way
has been to expose CD34+ cells to HIV in vitro and deter-
mine whether methylcellulose colonies from the cells con-
tain HIV sequences. Such studies detected low to absent
Figure 7. Surface expression of CXCR-4 and CKR-5 on CD34+ bone marrow cells
Matched isotype controls for CXCR-4 (A) and CKR-5 (D). Expression of CXCR-4 (B) and CKR-5 (E) on CD34+ cells. Positive single-stain controls using HOS-
CD4 (C) and transduced 293 (F) cells. Isotype controls for C and F are indicated in the figures at 2.0 and 1.8%, respectively.
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levels of infection in the colonies [21,42]. The second
approach has been to directly characterize CD34+ cells from
patients with HIV infection [20,22–24]. These studies also
pointed to a very low or absent level of infection of CD34+
cells, although very low levels were detected in MNC cells
before CD34 selection [23]. Nonetheless, it is still possible
that CD34+CD4+ cells are susceptible to HIV infection at
some stage, and that either they do not sustain viral produc-
tion or they are rapidly killed by the virus and therefore
viral sequences are not detected. 
The hypothesis that a subset of CD34+ cells might be
susceptible to HIV infection is supported by the finding
(reported here and by others) that these cells express mes-
sage for the HIV coreceptors CXCR-4 and CKR-5. We also
found that the cells expressed coreceptor protein on their
surface. Using cells from HIV– donors, Deichmann et al. [7]
showed that five of eight and two of eight CD34+CD4+ puri-
fied cells expressed CXCR-4 and CKR-5 message, respec-
tively, while seven of eight and one of eight CD34+CD4–
cells expressed CXCR-4 and CKR-5 message, respectively.
Our results with CXCR-4 are in general agreement with
Deichmann et al., showing expression on most samples of
CD34+ cells. However, we also found expression of CKR-5
in all MNC as well as CD34+ samples, while Deichmann et
al. found expression on only three of 16 total CD34+ sam-
ples examined. However, our FACS analysis shown in Fig. 7
confirms that a relatively low percentage of the population
actually express the CKR-5 protein on the cell surface. This
is consistent with the observation of Deichmann et al. 
While the CD34+-enriched populations were less than
100% pure, we believe the coreceptor expression was on
CD34+ cells and not contaminating cells for several reasons.
First, in Fig. 6, CD34+ samples 6 and 7 show a very similar
signal intensity even though the CD34+ purities were differ-
ent (98.5 and 86.4%, respectively; contaminating cells would
thus represent 1.5 and 13.6%). Second, the FACS analysis
showing expression of the protein on the surface of CD34+
cells is consistent with message expression in these cells.
Since these cells express HIV coreceptor along with
CD4, they should theoretically be targets for HIV infection;
however, high levels of HIV have not been reported in these
cells. Two possibilities could explain this. First, another
coreceptor required for HIV entry might not be expressed
in CD34+ cells. Alternatively, a cellular factor not present in
these cells might be required for sustained viral production.
Thus, the virus could get into the cell but would not repli-
cate efficiently. This idea is supported by a recent study
from Shen et al. [43].
Finally, the possibility exists that the CD34+CD4+ cells
are not infected by HIV but are indirectly impaired or
deleted by the virus or viral proteins. Consistent with that
Figure 8. No evidence for HIV sequences in CD34+ and MNC from HIV-infected patients
Nested RT-PCR for expression of HIV-RT sequences is shown. Cells were total mononuclear preparations (MNC) or CD34-selected (CD34). +/- refers to whether
reverse transcriptase was included in the reaction. Controls corresponded to 1 and 10 copies per genome of HIV-RT, as preciously described [35]. MilliQ (MQ)
water was included as a negative control. Sizes are indicated by the 123-bp ladder.
Figure 9. No evidence of HIV proviral sequences in CD34+ cells and
MNC from HIV-infected patients
DNA-based PCR for HIV-RT and b-actin is shown. Cell samples were a sub-
set of those shown in Figs. 6 and 8. Controls corresponded to 1 and 10 copies per
genome of HIV-RT. MilliQ (MQ) water was included as a negative control. 
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notion, we have demonstrated that CD34+ cells can specifi-
cally bind gp120 and that the cells undergo apoptosis as a
result. Apoptosis has been shown in both CD4+ and CD8+
T lymphocytes from HIV-infected individuals [44]. In
addition, crosslinking CD4 with gp120 and anti-gp120
upregulates expression of fas antigen in normal lympho-
cytes [8,45], consistent with the idea that gp120-CD4
interactions on the surface of CD4+ cells mediate apoptosis
[46]. It has recently been reported that apoptotic, uninfect-
ed CD4+ T cells in HIV-infected lymph nodes carry gp120
on their surface [47]. Another possibility is that infection
of adjacent cells such as stromal cells in the bone marrow
microenvironment might indirectly cause cell death of
progenitor cells by a similar mechanism as reported by
Badley et al. [48], where infected macrophage cells express-
ing fas ligand cause apoptosis of peripheral CD4 cells. An
indirect effect on early hematopoietic progenitors was pos-
tulated in a recent study by Jenkins et al. [49] in the SCID-
hu Thy/Liv model. In that study, depletion of progenitors
was demonstrated in SCID-hu mice grafts infected with
HIV-1, followed by a decline in thymocyte cell number.
Since proviral genomes were not detected in hemato-
poietic cells, the authors concluded that HIV acted indi-
rectly on hematopoietic cells, resulting in reduced colony-
forming units and, down the road, loss of mature thymo-
cytes. These data are entirely consistent with the studies
we report here. 
The exact mechanism of depletion of the CD34+CD4+
subpopulation in late-stage AIDS patients is not yet clear. As
discussed above, depletion could occur through direct inter-
action and infection with HIV or indirect mechanisms such
as apoptosis. Impairment of an early progenitor cell would
be manifested in defective thymopoiesis and peripheral
cytopenias such as observed in AIDS patients and would also
likely contribute to impaired immune reconstitution after
effective antiretroviral therapies. Our finding also suggests
that gene therapy approaches that use these cells as targets
for gene transfer and hematopoietic reconstitution in
patients need to be further evaluated. On one hand, the evi-
dence to date (low HLA-DR expression, BFU-E colony-
forming ability) suggests that these cells are early cells, and
so they might be a good choice for gene therapy in terms of
multilineage repopulation. On the other hand, our data
show that these cells are either directly or indirectly affected
by HIV, and so using these cells in late-stage patients might
not be fruitful. Ultimately, the exact function of the
CD34+CD4+ cell and its role in the pathogenesis of AIDS
needs to be defined before effective gene therapy approach-
es can be devised.
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